Journal of Clinical OncologyNeoadjuvant Chemoradiotherapy vs. Neoadjuvant Chemotherapy for Patients with Stage III-N2M0 Non-Small Cell Lung Cancer (NSCLC): A Population-Based Study

The authors investigated the effect of adding radiotherapy to neoadjuvant chemotherapy on survival in patients with Stage III-N2 non-small cell lung cancer. Analysis included 1,175 patients diagnosed between 2004 and 2015; 799 (68.0%) underwent neoadjuvant CRT and 376 (32.0%) underwent neoadjuvant CT. Adding radiotherapy to chemotherapy showed a slightly higher median OS than chemotherapy alone (51 vs. 47 months, respectively), and a higher median CSS (75 vs. 59 months, respectively). However, these differences were not statistically significant.